Patents by Inventor BELLICUM PHARMACEUTICALS, INC.

BELLICUM PHARMACEUTICALS, INC. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS
    Publication number: 20150111294
    Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 23, 2015
    Applicant: BELLICUM PHARMACEUTICALS, INC.
    Inventor: BELLICUM PHARMACEUTICALS, INC.
  • METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS
    Publication number: 20140087468
    Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.
    Type: Application
    Filed: February 8, 2013
    Publication date: March 27, 2014
    Applicant: BELLICUM PHARMACEUTICALS, INC.
    Inventor: BELLICUM PHARMACEUTICALS, INC.
  • METHODS FOR INDUCING SELECTIVE APOPTOSIS
    Publication number: 20130323834
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: March 6, 2013
    Publication date: December 5, 2013
    Applicant: BELLICUM PHARMACEUTICALS, INC.
    Inventor: BELLICUM PHARMACEUTICALS, INC.
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20130183333
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 18, 2013
    Applicant: BELLICUM PHARMACEUTICALS, INC.
    Inventor: BELLICUM PHARMACEUTICALS, INC.